Improving the identification of high-risk non-metastatic castration-resistant prostate cancer patients in clinical practice

Improving the identification of high-risk non-metastatic castration-resistant prostate cancer patients in clinical practice

Non-metastatic castration-resistant prostate cancer (nmCRPC) represents a challenging disease state in prostate cancer care. nmCRPC patients with a high risk of progression to metastatic disease who are identified by a prostate-specific antigen doubling time (PSADT) ≤10 months are eligible for treat...

Full description

Bibliographic Details
Main Authors: Alina Rosinha, Carlos Rabaça, Fernando Calais, João Moreira Pinto, João Vasco Barreira, Ricardo Fernandes, Rodrigo Ramos, Ana Cristina Fialho, José Palma dos Reis
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Oncology
Subjects:
high-risk
identification
non-metastatic castration-resistant prostate cancer
prostate-specific antigen
prostate-specific antigen doubling time
standardization
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1266369/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1266369/full

Similar Items